bupropion has been researched along with nadp in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kalgutkar, AS; Nguyen, HT | 1 |
Molnari, JC; Myers, AL | 1 |
Hollenberg, PF; Kenaan, C; Sridar, C | 1 |
3 other study(ies) available for bupropion and nadp
Article | Year |
---|---|
Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antidiarrheals; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dealkylation; Haloperidol; Humans; Hydroxylation; Ketoconazole; Loperamide; Male; Microsomes, Liver; NADP; Neurons; Pyridinium Compounds; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |
Carbonyl reduction of bupropion in human liver.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Alcohol Oxidoreductases; Antidepressive Agents, Second-Generation; Bupropion; Cytosol; Enzyme Inhibitors; Humans; Kinetics; Liver; Microsomes, Liver; NADP; Vitamin K 3 | 2012 |
Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
Topics: Amino Acid Sequence; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Aryl Hydrocarbon Hydroxylases; Bupropion; Chromatography, Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Escherichia coli; Glutathione; Heme; Humans; Hydroxylation; Molecular Sequence Data; NADP; Oxidoreductases, N-Demethylating; Peptides; Selegiline; Tandem Mass Spectrometry | 2012 |